Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: Photodermatol Photoimmunol Photomed. 2022 Aug 23;39(3):226–234. doi: 10.1111/phpp.12826

Figure 1:

Figure 1:

KDM1A inhibition modifies UV response: (A) HaCaT (immortalized keratinocytes) cells were treated with predetermined nontoxic doses of KDM1A inhibitor bizine (75–150μM) and exposed to solar simulated UV light (B,C) A panel of epithelial, melanocytic normal and cancer cells treated for 24 hours with vehicle or bizine (doses in Table S1) and then exposed to UVA-1 or UVB radiation. Cell viability was assessed 24 hours post irradiation KDM1A inhibition sensitizes cells to UVA radiation (D,E,F) Normal human keratinocytes (NHEKn), FaDu (squamous cell carcinoma) and HaCaT cells were treated with treated KDM1A inhibitor bizine and phenelzine and exposed to UVA light (G,I) mRNA expression by RT-qPCR and western blot for KDM1A downregulation using shRNA, sh1 and sh6 in HaCaT and FaDu cells (H,J) Effect of KDM1A downregulation on UVA irradiation. Cell viability is expressed as a percentage of control and was assessed using cell titer blue assay. Bars represent mean ± SD (n=3)